Ishara Investments LP Acquires Shares of 5,000 Ascendis Pharma A/S $ASND

Ishara Investments LP acquired a new stake in Ascendis Pharma A/S (NASDAQ:ASND) during the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 5,000 shares of the biotechnology company’s stock, valued at approximately $1,066,000. Ascendis Pharma A/S comprises 1.2% of Ishara Investments LP’s investment portfolio, making the stock its 27th biggest position.

A number of other hedge funds have also recently modified their holdings of the company. Perceptive Advisors LLC purchased a new position in shares of Ascendis Pharma A/S during the second quarter valued at about $166,367,000. Wellington Management Group LLP increased its position in shares of Ascendis Pharma A/S by 95.9% during the third quarter. Wellington Management Group LLP now owns 1,798,931 shares of the biotechnology company’s stock valued at $357,645,000 after buying an additional 880,836 shares during the period. Vestal Point Capital LP increased its position in shares of Ascendis Pharma A/S by 200.0% during the third quarter. Vestal Point Capital LP now owns 600,000 shares of the biotechnology company’s stock valued at $119,286,000 after buying an additional 400,000 shares during the period. Spyglass Capital Management LLC purchased a new position in shares of Ascendis Pharma A/S during the third quarter valued at about $77,267,000. Finally, Principal Financial Group Inc. increased its position in shares of Ascendis Pharma A/S by 29.3% during the fourth quarter. Principal Financial Group Inc. now owns 1,026,407 shares of the biotechnology company’s stock valued at $218,871,000 after buying an additional 232,730 shares during the period.

Wall Street Analysts Forecast Growth

ASND has been the topic of several research analyst reports. Royal Bank Of Canada boosted their price target on shares of Ascendis Pharma A/S from $250.00 to $275.00 and gave the company an “outperform” rating in a research report on Monday, March 2nd. Barclays boosted their price target on shares of Ascendis Pharma A/S from $342.00 to $345.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Cantor Fitzgerald reiterated an “overweight” rating and set a $300.00 price target on shares of Ascendis Pharma A/S in a research report on Monday, March 2nd. Wolfe Research reiterated an “outperform” rating and set a $260.00 price target on shares of Ascendis Pharma A/S in a research report on Monday, March 2nd. Finally, Evercore reiterated an “outperform” rating and set a $329.00 price target on shares of Ascendis Pharma A/S in a research report on Friday, May 15th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Ascendis Pharma A/S currently has an average rating of “Buy” and an average price target of $295.39.

Ascendis Pharma A/S Price Performance

Shares of ASND opened at $231.15 on Thursday. The stock has a market cap of $14.42 billion, a PE ratio of 26.66 and a beta of 0.39. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.72 and a current ratio of 1.00. Ascendis Pharma A/S has a fifty-two week low of $160.86 and a fifty-two week high of $250.74. The firm’s 50-day simple moving average is $232.16 and its two-hundred day simple moving average is $224.09.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $0.11. The business had revenue of $285.45 million during the quarter, compared to analysts’ expectations of $362.47 million. Analysts anticipate that Ascendis Pharma A/S will post 14.25 earnings per share for the current fiscal year.

Insider Transactions at Ascendis Pharma A/S

In other Ascendis Pharma A/S news, Director Jean Jacques Bienaime acquired 400 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were acquired at an average price of $237.80 per share, for a total transaction of $95,120.00. Following the completion of the acquisition, the director owned 400 shares in the company, valued at $95,120. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Flemming Steen Jensen sold 19,460 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $238.49, for a total transaction of $4,641,015.40. Additional details regarding this sale are available in the official SEC disclosure. 40.00% of the stock is currently owned by corporate insiders.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.